Biotech Values

[DewDiligence]

ANTICOAGULANT INDEX

[Updated for acceleration of Xarelto program.
Please see MNTA ‘ReadMeFirst’ for M118.]


General
#msg-25160571 Anticoagulant market has large potential (WSJ)
#msg-26899903 Anticoagulant market has large potential (graphic)
#msg-26451612 Venous thromboembolism is a big, big problem
#msg-18759853 Overview of the new oral anticoagulants
#msg-26701803 Technical overview of traditional anticoagulants


Xarelto (rivaroxaban)
#msg-30972846 EMEA approves Xarelto for VTE prevention
#msg-31857009 Bayer accelerates Xarelto development
#msg-31073048 JNJ submits NDA for VTE prevention
#msg-29662519 Rivaroxaban rationale
#msg-24337258 Bayer plans 50,000(!)-patient study


Apixaban
#msg-31742223 Apixaban fails vs Lovenox in phase-3
#msg-19134406 PFE, BMY ink $1B collaboration
#msg-29928836 Seventh and eighth phase-3 trials begin
#msg-21044973 Apixaban non-inferior to Warfarin in phase-2


Pradaxa (dabigatran)
#msg-27956748 Pradaxa approved for VTE prevention in EU
#msg-26086079 BI completes enrollment of huge AF trial
#msg-25152872 BI starts phase-2 in ACS
#msg-21155926 Dabigatran non-inferior to Lovenox in VTE prevention


Lovenox
#msg-11669012 Lovenox more cost-effective than heparin?
#msg-10569101 Arixtra bests Lovenox in ACS


Miscellaneous
#msg-31161411 AZD0837 comes out of the closet
#msg-30170392 ARYX ATI-5923: A safer warfarin?
#msg-29601951 Ablynx ALX-0081 begins phase-1b in PCI
#msg-27043616 ART-123 from Artisan Pharma
#msg-22938795 AVE5026 and otamixaban (SR123781 dropped Feb08)
#msg-26298260 Biotinylated idraparinux causes excess bleeding
#msg-30353872 MYGN MPC-0920 begins phase-1
#msg-31461171 NUVO reports phase-1b data for NU172
#msg-27187973 Paion’s Solulin completes phase-1
#msg-28742653 Paion acquires flovagatran rights
#msg-30965016 LLY terminates FXa program